Abstracts Archive - Page 1360 of 2607 - ACR Meeting Abstracts

Abstract Number: 2607 • 2018 ACR/ARHP Annual Meeting
Early Achievement of ASDAS-Major Improvement in Patients with Ankylosing Spondylitis Treated with TNF-α Blockers Is Associated with a Prominent Longterm Improvement in Metrologic Indices
Gi Bum Bae¹, Seungwoo Han², Jong Wan Kang², Jung Su Eun², Sang Jin Lee¹ and Eon Jeong Nam², ¹Internal medicine, Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of (South), ²Internal Medicine, Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of (South)
Background/Purpose: Limited spinal mobility is a cardinal sign of ankylosing spondylitis (AS) and shows a close relationship with functional disability which leads to high individual…
Abstract Number: 2608 • 2018 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study
Iain B. McInnes¹, Alan J. Kivitz², Peter Nash³, Proton Rahman⁴, Juergen Rech⁵, Bruce Kirkham⁶, Sandra V. Navarra⁷, Kevin Ding⁸, Emma Ilsley⁹ and Luminita Pricop¹⁰, ¹University of Glasgow, Glasgow, United Kingdom, ²Altoona Center for Clinical Research, Duncansville, PA, ³University of Queensland, Brisbane, Australia, ⁴Memorial University, St John's, NF, Canada, ⁵University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁷University of Santo Tomas Hospital, Manila, Philippines, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ
Background/Purpose: Secukinumab (SEC), a fully human monoclonal IgG1 antibody that selectively neutralizes IL-17A, provided sustained improvement in the signs and symptoms of active psoriatic arthritis…
Abstract Number: 2609 • 2018 ACR/ARHP Annual Meeting
Survival of Disease-Modifying Drugs in Patients with Recent Diagnosis of Psoriatic Arthritis in Daily Clinical Practice
Dalifer Freites Núñez¹, Zulema Rosales Rosado^1,2, Judit Font Urgelles², Isabel Hernández-Rodríguez², Leticia Leon¹, Gloria Candelas Rodriguez², Luis Rodriguez-Rodriguez¹, Benjamín Fernández-Gutiérrez^1,2, Juan A Jover Jover² and Lydia A Alcazar¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that benefits from DMARDs, in this regard knowing more about these therapies is a great step…
Abstract Number: 2610 • 2018 ACR/ARHP Annual Meeting
Certolizumab Pegol Serum Levels ≥20 Mg/L Are Associated with Treatment Response in Patients with Axial Spondyloarthritis
Johanna Gehin¹, Silje Watterdal Syversen², Guro Løvik Goll², David J Warren¹, Joseph Sexton³, Eldri Kvein Strand⁴, Tore Kvien^3,5,6, Elisabeth Lie^2,6 and Nils Bolstad⁷, ¹Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Lillehammer Revmatismesykehus, Lillehammer, Norway, ⁵NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁶On behalf of the NOR-DMARD registry, Oslo, Norway, ⁷Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway
Background/Purpose: Measurement of serum drug levels can help clinicians tailor treatment with TNF-inhibitors.An association between certolizumab pegol (CP) serum levels and response has previously been…
Abstract Number: 2611 • 2018 ACR/ARHP Annual Meeting
Multidrug Resistant AxSpA: No Advantage of Switching Class in Patients with Inadequate Response to Two Prior TNFi Agents
Sevket Ercan Tunc¹, Ismail Sari¹, Robert D Inman² and Nigil Haroon², ¹Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada
Background/Purpose: Lack of efficacy (LOE) to TNF inhibitor (TNFi) treatments is an important issue and can be seen in up to 40% of the patients…
Abstract Number: 2612 • 2018 ACR/ARHP Annual Meeting
Utility of Infiltration with Steroids in Dactilitis. Is the Infiltration Guided By Ecography Better THAN Conventional?
Rosalia Martinez Pérez¹, Alberto Ruiz Roman², Esteban Rubio-Romero³, Clara Aguilera Cros¹, Elena Alonso¹ and Juan Povedano⁴, ¹Rheumatology, University Hospital Virgen del Rocío, Seville, Spain, ²Department of Rheumatology, Hospital Virgen del Rocio, Seville, Spain, ³Hospital Universitario Virgen del Rocío. Sevilla. Spain, Sevilla, Spain, ⁴Rheumatology, University Hospital Virgen del Rocío, Sevilla, Spain
Background/Purpose: Dactylitis, also called "sausage fingers", is considered one of the differential signs characteristic of Spondyloarthritis (SpA). The absence of knowledge of its pathophysiology make…
Abstract Number: 2613 • 2018 ACR/ARHP Annual Meeting
Patterns of Medication Use in a Validated Cohort of Psoriatic Arthritis (PsA) Patients
Madeline J. Epsten¹, Lisa A. Mandl¹, Jackie Szymonifka² and Sergio Schwartzman¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: There is currently a lack of consensus among experts on the optimal therapeutic management of psoriatic arthritis (PsA). EULAR and GRAPPA recommendations support initial…
Abstract Number: 2614 • 2018 ACR/ARHP Annual Meeting
The Effect of Secukinumab on the Immunogenicity of Influenza Vaccine in Patients with Psoriatic Arthritis
Ori Elkayam¹, Devy Zisman², Ilana Kaufman³, Uri Arad⁴, Mark Berman⁵, Victoria Furer⁶, Yael Lahat¹, Or Carmi¹, Amir Haddad⁷, Muna Elias⁷, Daphna Paran¹ and Michal Mandelbaum⁸, ¹Department of rheumatology, Tel Aviv medical center and the Sackler Faculty of medicine, Tel Aviv University, Tel Aviv, Israel, ²Technion, Rheumatology Unit Carmel Medical Center, Haifa, Israel, ³Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁴Rheumatology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel, ⁵Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel, ⁷Rheumatology Unit Carmel Medical Center, Haifa, Israel, ⁸Sheba medical center, Ramat Gan, Israel
Background/Purpose: The humoral response to vaccination may be affected by the use of immunosuppressive drugs. The effect of secukinumab on the humoral response of vaccines…
Abstract Number: 2615 • 2018 ACR/ARHP Annual Meeting
The Effect of Smoking on Response to Tumour Necrosis Factor-Alpha Inhibitor Treatment in Psoriatic Arthritis Patients: Results from the Turkbio Registry
Handan Yarkan¹, Gokce Kenar¹, Sedat Capar², Gerçek Can¹, Berrin Zengin¹, Servet Akar³, Ediz Dalkiliç⁴, Soner Senel⁵, Suleyman Serdar Koca⁶, Abdurrahman Tufan⁷, Ayten Yazici⁸, Nevsun İnanç⁹, Hülya Ellidokuz¹⁰, Nurullah Akkoc¹¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Statistics, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ³Department of Internal Medicine, Division of Rheumatology,, Izmir Katip Çelebi University Faculty of Medicine, Izmir, Turkey, ⁴Department of Internal Medicine, Division of Rheumatology, Uludağ University Faculty of Medicine, Bursa, Turkey, ⁵Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, ⁶Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, ⁷Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, ⁸Rheumatology, Kocaeli University, Faculty of Medicine, Kocaeli, Turkey, ⁹Rheumatology, Marmara University faculty of Medicine, İstanbul, Turkey, ¹⁰Statistics, Dokuz Eylül Üniversity Faculty of Medicine, IZMIR, Turkey, ¹¹Rheumatology, İzmir, Turkey, İzmir, Turkey
Background/Purpose: The aim of the study was to investigate the impact of smoking on disease activity, treatment adherence and treatment response in psoriatic arthritis (PsA)…
Abstract Number: 2616 • 2018 ACR/ARHP Annual Meeting
The Effect of Smoking on Response to Tumor Necrosis Factor-Alpha Inhibitor Treatment in Ankylosing Spondylitis Patients: Results from the Turkbio Registry
Handan Yarkan¹, Gerçek Can¹, Sedat Capar², Berrin Zengin¹, Gokce Kenar¹, Servet Akar³, Ediz Dalkiliç⁴, Soner Senel⁵, Suleyman Serdar Koca⁶, Abdurrahman Tufan⁷, Ayten Yazici⁸, Nevsun İnanç⁹, Hülya Ellidokuz¹⁰, Nurullah Akkoc¹¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Statistics, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ³Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁴Department of Internal Medicine, Division of Rheumatology, Uludağ University Faculty of Medicine, Bursa, Turkey, ⁵Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, ⁶Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, ⁷Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, ⁸Rheumatology, Kocaeli University, Faculty of Medicine, Kocaeli, Turkey, ⁹Rheumatology, Marmara University faculty of Medicine, İstanbul, Turkey, ¹⁰Statistics, Dokuz Eylül Üniversity Faculty of Medicine, IZMIR, Turkey, ¹¹Rheumatology, İzmir, Turkey, İzmir, Turkey
Background/Purpose: Although there is good evidence that smoking has a dose-dependent impact on structural damage progression in ankylosing spondylitis (AS) the evidence is poor for its…
Abstract Number: 2617 • 2018 ACR/ARHP Annual Meeting
Prolonged Effectiveness of a 12 Week Regimen of Biosimilar Adalimumab in Indian (Asian) Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis (AS)
Arvind Chopra¹, Nagnath Khadke², Manjit Saluja³, Toktam Kainifard⁴ and Anuradha Venugopalan⁵, ¹Center for Rheumatic Diseases, Pune, India, ²Rheumatolgy, Consultant, Pune, India, ³Rheumatology, Research Co-ordinator, Pune, India, ⁴Rheumatology, Consultant research and Dietitian, Tehran, Iran (Islamic Republic of), ⁵Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India
Background/Purpose: On regulatory approval in India, challenging socioeconomics and infection prone scenario compelled us to seek prolonged effectiveness of short term anti-TNF therapeutic regimen (Chopra…
Abstract Number: 2618 • 2018 ACR/ARHP Annual Meeting
Drug Survival of Non TNF Inhibitors Bdmards in Psoriatic Arthritis (Ustekinumab/Secukinumab) : A Real-Word Multicentric Cohort of 161 Patients
Jean-Guillaume Letarouilly¹, Jeremie Sellam², Pascal Richette³, Philippe Dieude⁴, Pascal Claudepierre⁵, Tristan Pascart⁶, Eric Houvenagel⁶, Marie-Hélène Guyot⁷, Nicolas Segaud⁸, Pascal Coquerelle⁹, Frederic Maury¹⁰, Laurent Marguerie¹¹, Xavier Deprez¹², Jean-Hugues Salmon¹³, Guy Baudens¹², Elisabeth Gervais¹⁴, Maeva Kyheng¹⁵, Julien Paccou¹ and René-Marc Flipo¹, ¹Rheumatology, Lille University Hospital, Lille, France, ²AP-HP Saint-Antoine hospital, Service de Rhumatologie, Inserm UMRS_938, Paris, France, ³Rheumatology, Université Paris Diderot, Paris, France, ⁴Université Paris-Diderot, Paris, France, ⁵Hôpital Henri Mondor, Créteil, France, ⁶Rheumatology, Groupe Hospitalier de l'Institut Catholique de Lille, Lomme, France, ⁷Internal medicine, Hospital of Roubaix, Roubaix, France, ⁸Internal medicine, Hospital of Armentieres, Armentières, France, ⁹rheumatology, Hospital of Bethune, Bethune, France, ¹⁰Rheumatology, Private Practice, Beuvry, France, ¹¹Rheumatology, Institut Calot, Berck, France, ¹²Rheumatology, CHR Valenciennes, Valenciennes, France, ¹³Service de Rhumatologie, CHU Reims, Hôpital Maison Blanche, Reims, France, ¹⁴Rhumatologie, University Hospital, Poitiers, France, ¹⁵Lille University Hospital, EA 2694 - Santé publique : épidémiologie et qualité des soins, F-59000, Lille, France
Background/Purpose: Ustekinumab and secukinumab are two new Biologic Disease-modifying Antirheumatic Drugs (bDMARDs) in severe psoriatic arthritis (PsA), targeting respectively IL12-23 and IL 17. Data in…
Abstract Number: 2619 • 2018 ACR/ARHP Annual Meeting
Effect of Statins on CRP Elevation in Patients with Psoriatic Arthritis
Lesley Jackson¹, Jeffry Bieber^1,2 and R. Eric Heidel³, ¹Graduate School of Medicine, Department of Internal Medicine, University of Tennessee Medical Center Knoxville, Knoxville, TN, ²UT Rheumatology, Knoxville, TN, ³Graduate School of Medicine, Division of Biostatistics, and Department of Surgery, University of Tennessee Medical Center Knoxville, Knoxville, TN
Background/Purpose: It is well established that psoriatic arthritis is associated with increased cardiovascular disease risk. The use of statins may impart anti-inflammatory effects, possibly through…
Abstract Number: 2620 • 2018 ACR/ARHP Annual Meeting
The Treatment Choices and Response for a Psoriatic Arthritis Inception Cohort
Umut Kalyoncu¹, Abdulsamet Erden¹, Gezmis Kimyon², Timucin Kasifoglu³, Atalay Dogru⁴, Ozun Bayndır⁵, Ediz Dalkiliç⁶, Cem Ozisler¹, Ayse Balkarli¹, Gozde Cetin⁷, Rıdvan Mercan⁸, Orhan Kucuksahin¹, Ahmet Omma¹, Serpil Ergullu Esmen⁹, Levent Kilic¹, Dilek Solmaz¹⁰, Muhammet Cinar¹, Seval Pehlevan¹¹, Sema Yilmaz⁹, Tuncay Duruoz¹¹, Sibel Bakirci⁵ and Sibel Zehra Aydın¹², ¹PsART study group, Ankara, Turkey, ²PsART study group, Hatay, Turkey, ³PsART study group, Eskişehir, Turkey, ⁴PsART study group, Isparta, Turkey, ⁵PsART study group, Izmir, Turkey, ⁶PsART study group, Bursa, Turkey, ⁷PsART study group, Kahramanmaras, Turkey, ⁸PsART study group, Tekirdag, Turkey, ⁹PsART study group, Konya, Turkey, ¹⁰PsART study group, Ottawa, OH, Canada, ¹¹PsART study group, Istanbul, Turkey, ¹²PsART study group, Ottawa, ON, Canada
Background/Purpose: There had been a lot of new therapeutic agents for the treatment of Psoriatic Arthritis (PsA) in the last decade. In this study we…
Abstract Number: 2621 • 2018 ACR/ARHP Annual Meeting
Predictors of Survival of Adalimumab Treatment in the Management of Ankylosing Spondylitis and Psoriatic Arthritis in Canadian Routine Care
Louis Bessette^1,2, Majed Khraishi³, Jacqueline Stewart^4,5, Andrew Chow^6,7, Viktoria Pavlova⁸, Brandusa Florica^6,9 and Valencia P. Remple^10,11, ¹Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, ²Rheumatology, Laval University, Quebec, QC, Canada, ³Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Penticton Regional Hospital, Penticton, BC, Canada, ⁵University of British Columbia, Penticton, BC, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Trillium Health Partners Credit Valley Hospital, Mississauga, ON, Canada, ⁸McMaster University, Hamilton, ON, Canada, ⁹Trillium Health Partners, Mississauga, ON, Canada, ¹⁰AbbVie Corporation, Montreal, QC, Canada, ¹¹School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Biologics therapy survival is often used as a proxy for treatment effectiveness and safety. However, it may be influenced by patient characteristics, utilization patterns,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].